Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about treatment/resistant depression
Recent news which mentions treatment/resistant depression
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
July 23, 2024
Tickers
JNJ
NEWS
Tags
JNJ
eketamine nasal spray
premium
From
Benzinga
First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
April 26, 2024
Tickers
NEWS
Tags
News
Beckley Psytech Ltd
Rob Conley
From
Benzinga
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
March 28, 2024
Tickers
ATAI
NEWS
Tags
Biotech
Psychedelics
Benzinga
From
Benzinga
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
February 29, 2024
Tickers
CMPS
Tags
Benzinga
Psychedelics
2023 financial results
From
Benzinga
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
November 15, 2023
Tickers
AWKNF
CMPS
Tags
Psychedelic/Assisted Therapies
Legal
CMPS
From
Benzinga
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
October 03, 2023
Tickers
ATAI
Tags
Management
Psychedelic/Assisted Therapies
Benzinga
From
Benzinga
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
September 06, 2023
Tickers
CMPS
Tags
Machine/Learning Research
News
Guidance
From
Benzinga
GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026
August 24, 2023
Tickers
GHRS
Tags
treatment/resistant depression
Cannabis
Market News
From
Benzinga
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
July 18, 2023
Tickers
CMPS
Tags
treatment/resistant depression
Markets
Market News
From
Benzinga
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
July 05, 2023
Tickers
ATAI
CMPS
HTGC
Tags
Psychedelics Financing
Benzinga
Psychedelics
From
Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
May 30, 2023
Tickers
CMPS
NUMIF
Tags
Psilocybin program
Benzinga
Psychedelics
From
Benzinga
GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer
May 11, 2023
Tickers
GHRS
Tags
Psychedelic/Assisted Therapies
Small Cap
General
From
Benzinga
Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
May 04, 2023
Tags
treatment/resistant depression
Markets
Cannabis
From
Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
January 12, 2023
Tickers
ATAI
CMPS
IGXT
Tags
treatment/resistant depression
Markets
Market News
From
Benzinga
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
December 12, 2022
Tickers
CMPS
Tags
News
treatment/resistant depression
Markets
From
Benzinga
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
December 09, 2022
Tickers
CMPS
Tags
treatment/resistant depression
Compass Pathways
Markets
From
Benzinga
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes
November 16, 2022
Tickers
CMPS
Tags
Markets
Psilocybin
Market News
From
Benzinga
Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders
November 02, 2022
Tags
Lusaris Therapeutics
News
Markets
From
Benzinga
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
October 05, 2022
Tickers
ATAI
Tags
Benzinga
Psychedelics
Penny Stocks
From
Benzinga
Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compound
July 28, 2022
Tickers
CMPS
Tags
Anorexia Nervosa
Benzinga
Psychedelics
From
Benzinga
Psilocybin More Effective Than Antidepressants In Treating Depression, New Study Shows
April 12, 2022
Tags
News
Psychology
Market News
From
Benzinga
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
December 01, 2021
Tickers
CMPS
Tags
Benzinga
Biotech
Peter Thiel
From
Benzinga
Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying
November 16, 2021
Tickers
GHRS
Tags
Sonoran desert toad
Benzinga
Small Business
From
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit